Foundry Healthcare 12-Month Momentum Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 10.80% |
2CNC | CENTENE CORP | Healthcare | $32.81B | 8.95% |
3ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 6.77% |
4GH | GUARDANT HEALTH INC | Healthcare | $20.67B | 5.64% |
5BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $13.71B | 3.74% |
6ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 2.86% |
7APGE | APOGEE THERAPEUTICS INC | Healthcare | $10.10B | 2.76% |
8KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 2.60% |
9PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $8.77B | 2.39% |
10SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 2.37% |
11IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 2.19% |
12PACS | PACS GROUP INC | Healthcare | $7.30B | 1.99% |
13LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 1.94% |
14COGT | COGENT BIOSCIENCES INC | Healthcare | $6.68B | 1.82% |
15CGON | CG ONCOLOGY INC | Healthcare | $6.34B | 1.73% |
16ERAS | ERASCA INC | Healthcare | $5.96B | 1.63% |
17TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 1.59% |
18DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 1.58% |
19ORKA | ORUKA THERAPEUTICS INC | Healthcare | $5.59B | 1.53% |
20TXG | 10X GENOMICS INC | Healthcare | $5.55B | 1.52% |
21TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 1.44% |
22DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.83B | 1.32% |
23VCYT | VERACYTE INC | Healthcare | $4.72B | 1.29% |
24LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $4.49B | 1.23% |
25CELC | CELCUITY INC | Healthcare | $4.31B | 1.18% |
26EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $4.28B | 1.17% |
27TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 1.13% |
28RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 1.04% |
29ALMS | ALUMIS INC | Healthcare | $3.65B | 1.00% |
30GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $3.45B | 0.94% |
31RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 0.94% |
32ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.24B | 0.88% |
33MBX | MBX BIOSCIENCES INC | Healthcare | $2.99B | 0.82% |
34TRVI | TREVI THERAPEUTICS INC | Healthcare | $2.71B | 0.74% |
35KOD | KODIAK SCIENCES INC | Healthcare | $2.67B | 0.73% |
36QURE | UNIQURE NV | Healthcare | $2.54B | 0.69% |
37SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $2.45B | 0.67% |
38NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 0.63% |
39PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.26B | 0.62% |
40SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.61% |
41AXGN | AXOGEN INC | Healthcare | $2.12B | 0.58% |
42GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $2.07B | 0.57% |
43RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $2.04B | 0.56% |
44DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.94B | 0.53% |
45TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.91B | 0.52% |
46NEO | NEOGENOMICS INC | Healthcare | $1.90B | 0.52% |
47MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.51% |
48BCAX | BICARA THERAPEUTICS INC | Healthcare | $1.82B | 0.50% |
49STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.49% |
50BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.47% |
51TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 0.47% |
52ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.46% |
53FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.46% |
54CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.67B | 0.45% |
55PSNL | PERSONALIS INC | Healthcare | $1.61B | 0.44% |
56INNV | INNOVAGE HOLDING CORP | Healthcare | $1.56B | 0.43% |
57SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.41% |
58ABSI | ABSCI CORP | Healthcare | $1.29B | 0.35% |
59INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.35% |
60CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $1.25B | 0.34% |
61DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.19B | 0.33% |
62ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.32% |
63CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $1.13B | 0.31% |
64JBIO | JADE BIOSCIENCES INC | Healthcare | $1.03B | 0.28% |
65BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 0.28% |
66ANRO | ALTO NEUROSCIENCE INC | Healthcare | $967M | 0.26% |
67AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.22% |
68ACRS | ACLARIS THERAPEUTICS INC | Healthcare | $793M | 0.22% |
69DSGN | DESIGN THERAPEUTICS INC | Healthcare | $785M | 0.21% |
70CLYM | CLIMB BIO INC | Healthcare | $727M | 0.20% |
71OMER | OMEROS CORP | Healthcare | $701M | 0.19% |
72TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.18% |
73ACHV | ACHIEVE LIFE SCIENCES INC | Healthcare | $644M | 0.18% |
74STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.16% |
75FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.16% |
76IMMX | IMMIX BIOPHARMA INC | Healthcare | $558M | 0.15% |
77RLMD | RELMADA THERAPEUTICS INC | Healthcare | $550M | 0.15% |
78CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.15% |
79ZURA | ZURA BIO LTD | Healthcare | $518M | 0.14% |
80NVCT | NUVECTIS PHARMA INC | Healthcare | $508M | 0.14% |
81KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $453M | 0.12% |
82PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.12% |
83STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.11% |
84ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.10% |
85QTTB | Q32 BIO INC | Healthcare | $255M | 0.07% |
86SRZN | SURROZEN INC | Healthcare | $255M | 0.07% |
87ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.07% |
88KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.06% |
89BDSX | BIODESIX INC | Healthcare | $204M | 0.06% |
90FOCL | FOCAL INC | Healthcare | $204M | 0.06% |
91VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.04% |
92SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.03% |
93RLYB | RALLYBIO CORP | Healthcare | $87M | 0.02% |
94NRXS | NEURAXIS INC | Healthcare | $84M | 0.02% |
95EDSA | EDESA BIOTECH INC | Healthcare | $59M | 0.02% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $366.51B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 86% toward Large, 64% toward Growth. +11% unclassified (11 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 43.8% | -5.1% |
| 3 yearsp.a. | 21.8% | 5.9% |
| 5 yearsp.a. | 7.2% | 6.5% |
| 10 yearsp.a. | 14.1% | 5.6% |
| Since inceptionp.a. | 13.0% | 0.8% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 22.4% | 11.7% |
| 2025 | 17.9% | 1.8% |
| 2024 | 32.7% | 29.8% |
| 2023 | -9.5% | -34.8% |
| 2022 | -10.0% | 29.0% |
| 2021 | 19.8% | 28.8% |
| 2020 | 40.6% | -8.6% |
| 2019 | 29.8% | -8.8% |
| 2018 | -12.9% | -0.6% |
| 2017 | 37.4% | 23.6% |
| 2016 | -20.2% | 19.8% |
| 2015 | -18.6% | -36.1% |
| 2014 | 21.9% | -14.9% |
| 2013 | 72.7% | 27.2% |
| 2012 | 22.2% | -9.4% |
| 2011 | 22.8% | 20.5% |
| 2010 | 12.1% | -12.0% |
| 2009 | 25.8% | -19.7% |
| 2008 | -20.6% | -3.2% |
| 2007 | 16.8% | 37.1% |
| 2006 | -9.6% | -22.8% |
| 2005 | 18.0% | 20.6% |
| 2004 | 20.6% | 9.7% |
| 2003 | 48.6% | 0.1% |
| 2002 | -23.8% | 1.3% |
| 2001 | -0.3% | -7.6% |
| 2000 | 21.7% | -30.4% |
| 1999 | 51.5% | 33.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare 12-Month Momentum Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 12-Month Momentum signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.